Back to Journals » International Journal of Chronic Obstructive Pulmonary Disease » Volume 9 » Issue 1

Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge

Authors Golzar Y, Doukky R

Received 31 October 2013

Accepted for publication 6 December 2013

Published 22 January 2014 Volume 2014:9(1) Pages 129—137


Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yasmeen Golzar,1,2 Rami Doukky1,2

1Division of Adult Cardiology, John H Stroger Jr, Hospital of Cook County, 2Division of Cardiology, Rush University Medical Center, Chicago, IL, USA

Abstract: Stress testing is challenging in patients with chronic obstructive pulmonary disease (COPD). Functional capacity is generally decreased in this patient population, limiting patients' ability to achieve physiologic stress through exercise. Additionally, due to emphysematous changes, COPD patients tend to have poor acoustic windows that impair the quality and therefore diagnostic accuracy of stress echocardiography techniques. Pharmacologic stress myocardial perfusion imaging (MPI) testing is also problematic, particularly due to the concern for adenosine-induced bronchoconstriction with conventional vasodilator stress agents. Regadenoson, a selective A2A adenosine receptor agonist, has gained popularity due to its ease of administration and improved patient experience in the general population. The literature describing the experience with regadenoson in COPD patients, though limited, is rapidly growing and reassuring. This review summarizes the pharmacology and clinical application of this novel stress agent and presents the available data on the safety and tolerability of its use in COPD patients.

Keywords: chronic obstructive pulmonary disease, COPD, regadenoson, myocardial perfusion imaging, safety, tolerability, asthma, emphysema

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]


Readers of this article also read:

Ultraviolet light and laser irradiation enhances the antibacterial activity of glucosamine-functionalized gold nanoparticles

Govindaraju S, Ramasamy M, Baskaran R, Ahn SJ, Yun KS

International Journal of Nanomedicine 2015, 10:67-78

Published Date: 25 August 2015

Today's diverse nano-theranostic applications and tomorrow's promises

Webster TJ, Lee S, An SSA

International Journal of Nanomedicine 2015, 10:1-2

Published Date: 25 August 2015

Sex-specific relationships between adverse childhood experiences and chronic obstructive pulmonary disease in five states

Cunningham TJ, Ford ES, Croft JB, Merrick MT, Rolle IV, Giles WH

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:1033-1043

Published Date: 26 September 2014

Sleep hypoventilation and daytime hypercapnia in stable chronic obstructive pulmonary disease

Holmedahl NH, Øverland B, Fondenes O, Ellingsen I, Hardie JA

International Journal of Chronic Obstructive Pulmonary Disease 2014, 9:265-275

Published Date: 27 February 2014